• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Marta Milà Alomà

2020-10-30News

Could you tell us a bit about you and your work?

My background lies in the fields of neurobiology and neuropsychology, and I am currently a PhD student at Barcelonabeta Brain Research Center. My research focuses on the study of fluid biomarker profiles in preclinical Alzheimer’s disease, as well as on the effect of modifiable and non-modifiable risk factors on these biomarkers in the early stage of the disease. I have a special interest in studying whether there are sex differences in fluid biomarkers reflecting different pathophysiological pathways, and on the effect of risk and protective factors on brain pathology. I think this research can provide very valuable knowledge to better understand the disease development and potentially contribute in the design of effective preventive and therapeutic strategies.

Besides my work as a researcher, I have also been involved in the coordination of EPAD WP1: “Scientific challenges”.

 

You are a member of the EPAD WP1 “Scientific challenges”. Could you please tell us more about its work and main achievements?

EPAD WP1 was created to address scientific challenges related to the design and execution of the study throughout its duration. The main challenges included the definition of a risk spectrum of research participants suitable for secondary prevention, the development of evaluation criteria for inclusion to the project based on biomarker and clinical endpoints, and the assessment and selection of potential trial mechanisms and compounds.

To address these objectives, WP1 was informed and advised through the creation of five different Scientific Advisory Groups (SAGs), which provided key scientific input and support. These were the Imaging SAG, the Clinical and Cognitive outcomes SAG, the Genetics SAG, the Fluid biomarkers SAG and, finally, the Lifestyle and non-pharmacological interventions SAG.

Each of these SAGs has crucially contributed providing evidence and recommendations in relation to the study inclusion criteria, assessments and endpoints. Importantly, their recommendations and white papers resulted in publications in high impact scientific journals.

Besides this, WP1 has also been involved in research access procedures, giving support in the creation of research access committees and processes to receive and manage research applications and to grant access to EPAD data and samples to EPAD partners and also to external researchers. The creation of these processes has allowed the provision of high-quality research data open for the research community through a systematized and overseen research access process.

 

What value do you see in public-private collaboration and networking with related initiatives?

From my perspective, the public-private collaboration has represented an advantage in the context of the design and execution of EPAD.

Experts in the field from Academy have been key providing scientific input and addressing the challenging questions and decisions to design a high quality and scientifically valuable trial-ready observational cohort such as EPAD. On the other hand, industry partners are crucial for their expertise on study protocols design and implementation. They have also been key for the management of the different trial delivery centres across Europe, and for the development of tools allowing efficient data collection and access processes.

 

What are the most prominent challenges you see in Alzheimer’s disease research?

Recent research in Alzheimer’s disease is showing very promising evidence on potential therapeutic candidates which, if proved to be effective, might represent a breakthrough advancement towards the possibility to control or prevent the disease progression in Alzheimer’s patients.

Also, many efforts are being put at understanding the physiopathology of the disease in its preclinical phase, years before clinical manifestations arise. A better understanding of the pathophysiological cascade occurring in this early stage would help to identify potential intervention targets. Also, besides seeking pharmacological intervention candidates, non-pharmacological interventions are getting growing interest among the research community, with the aim to find preventive strategies that avoid or delay the onset of dementia.

The heterogeneity in terms of pathological mechanisms and trajectories between individuals is a prominent challenge in the field. The development of the disease is influenced by multiple factors such as sex, gender, race, or lifestyle. Therefore, in my opinion, this is a highly relevant topic that should be further addressed, in order to progress towards precision medicine approaches that enable prevention and therapeutic strategies suitable and effective for each particular risk group.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT